Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + lenalidomide
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sintilimab + lenalidomide is a combination therapy that pairs a PD-1 immune checkpoint inhibitor (sintilimab) with an immunomodulatory drug (lenalidomide). This combination has been studied for various conditions including chronic active Epstein-Barr virus infection (CAEBV) and certain lymphomas. The combination works through complementary mechanisms - sintilimab blocks the PD-1 pathway to enhance T-cell immune responses against cancer cells, while lenalidomide modulates the immune system, has anti-angiogenic properties, and directly affects tumor cells. In clinical studies, this combination has shown efficacy with manageable safety profiles.
- Brand names
- TyvytRevlimid
- Other names
- PD-1 antibody and lenalidomidePD1 antibody and lenalidomidePD 1 antibody and lenalidomidesintilimab and lenalidomidePD-1 antibody-Beijing Friendship Hospital-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis-chronic active Epstein-Barr virus infectionPD1 antibody-Beijing Friendship Hospital-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis-chronic active Epstein-Barr virus infectionPD 1 antibody-Beijing Friendship Hospital-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis-chronic active Epstein-Barr virus infection
02
Targets
CRBN (Cereblon)PDCD1 (Programmed cell death protein 1 receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on sintilimab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + lenalidomide.